Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prediction of preeclampsia in type 1 diabetes in early pregnancy by clinical predictors: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Maternal serum laeverin (aminopeptidase Q) measured in the first trimester of pregnancy does not predict preeclampsia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Continuous focus on preventive strategies and follow-up is important for a change

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lessons learnt from anonymized review of cases of peripartum hysterectomy by international experts: A qualitative pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The increasing role of a retained placenta in postpartum blood loss: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Defining definitions: a Delphi study to develop a core outcome set for conditions of severe maternal morbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background and objectives: To explore if intravenous iron isomaltoside (Monofer ®) leads to a better relief of fatigue than current treatment practice with oral iron in women suffering from severe fatigue after postpartum hemorrhage. Materials and methods: This is a subanalysis of a single-center, open-label, randomized controlled trial conducted in women suffering from postpartum hemorrhage. Participants were randomized 1:1 to 1200 mg iron isomaltoside or current treatment practice with oral iron. We measured fatigue by the Multidimensional Fatigue Inventory (MFI) and Edinburgh Postnatal Depression Scale, and determined hematological parameters. The subanalysis includes all participants with a high fatigue score (MFI physical fatigue score >15) at inclusion. The primary endpoint was aggregated change in physical fatigue score from inclusion to 12 weeks postpartum with a predefined minimum clinically relevant difference of 1.8. The trial is registered at ClinicalTrials.gov (identifier: NCT01628770). Results: A total of 85 women had a high fatigue score at inclusion. The aggregated change in physical fatigue score was −2.3 (confidence interval 95%: −3.3; −1.3) (p < .0001) in favor of iron isomaltoside. Significant differences in other fatigue and depression scores and hematological parameters were observed and all in favor of iron isomaltoside. There were no differences in side effects between the groups. Conclusions: In women suffering from severe fatigue after postpartum hemorrhage, a single dose of iron isomaltoside is associated with a statistically significant and clinically relevant reduction in aggregated physical fatigue within 12 weeks after delivery, when compared to current treatment practice with oral iron and with a similar safety profile.

Original languageEnglish
JournalThe journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Volume32
Issue number17
Pages (from-to)2797-2804
Number of pages8
ISSN1476-7058
DOIs
Publication statusPublished - Sep 2019

    Research areas

  • Journal Article, intravenous iron, postpartum hemorrhage, Anemia, iron deficiency, postpartum depression

ID: 53475196